Change over period: —
NSE · AARTIDRUGS
AARTI DRUGS
-0.6% from the 52-week high · +58.2% above the low
Aarti Drugs Ltd. engages in the development, manufacture and market of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 1,500 full-time employees. The firm operates through pharmaceuticals segment. The firm's APIs products include ciprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole and ofloxacin, among others. Its specialty chemicals products include benzene sulphonyl chloride and methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include itraconazole, fluconazole, dabigatran, ticagrelor, sitagliptin and alpha lipoic acid. The firm's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SPA.
The short version. AARTI DRUGS reported revenue of ₹826 crore for Sep 2026, up 26.5% from a year earlier. Net profit was ₹83 crore (up 84.4% year on year). Return on equity was 12.6% in Mar 2026. Promoter holding was 54.07% in Sep 2026, down 1.31 points over 8 quarters.
1 · The price
How has the stock traded?
AARTI DRUGS trades 0.6% below its 52-week high and 58.2% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹826 cr.
Sep 2026 net profit of ₹83 cr.
3.1 pts higher than a year earlier.
Revenue compounded at -1.9% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 826 | 703 | 720 | 602 | 653 | 591 | 677 | 557 |
| Net profit | 83 | 50 | 55 | 41 | 45 | 54 | 63 | 37 |
| Net margin % | 10.0 | 7.1 | 7.7 | 6.7 | 6.9 | 9.1 | 9.3 | 6.7 |
| EPS (₹) | 9.09 | 5.5 | 6.05 | 4.44 | 4.96 | 5.91 | 6.89 | 4.06 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2565 | 2387 | 2529 | 2716 | 2489 | 2155 | 1806 | 1561 |
| Net profit | 195 | 168 | 171 | 166 | 205 | 280 | 141 | 90 |
| Net margin % | 7.6 | 7.0 | 6.8 | 6.1 | 8.2 | 13.0 | 7.8 | 5.7 |
| EPS (₹) | 21.36 | 18.42 | 18.65 | 17.96 | 22.14 | 30.09 | 15.17 | 9.51 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 12.6% in Mar 2026; debt to equity is 0.37.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 12.6 | 12.3 | 13.4 | 14.0 |
| Return on capital % | 12.9 | 14.2 | 16.4 | 17.3 |
| EBITDA margin % | 12.1 | 12.6 | 12.7 | 11.3 |
| Net margin % | 7.6 | 7.0 | 6.8 | 6.1 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | -1.9% | 3.5% |
| Profit CAGR | 5.4% | -7.0% |
4 · The owners
Who holds it, and are they adding?
Down 1.31 pts over 8 quarters.
Down 0.02 pts over 8 quarters.
Up 1.47 pts over 8 quarters.
+2 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 55.38 | 55.48 | 55.22 | 54.72 | 55.03 | 55.03 | 54.43 | 54.07 | -1.31 |
| FII | 2.28 | 2.25 | 2.26 | 2.69 | 2.15 | 1.58 | 1.52 | 2.26 | -0.02 |
| DII | 8.77 | 9.7 | 9.94 | 9.9 | 10.12 | 10.22 | 10.29 | 10.24 | +1.47 |
| Public | 33.57 | 32.57 | 32.58 | 32.69 | 32.7 | 33.18 | 33.75 | 33.43 | -0.14 |
Mutual fund holdings · Oct 2026
8 schemes hold this stock
6 the month before.
- DSP Small Cap Fund1.37% of NAV
- ICICI Prudential Healthcare Fund1.0% of NAV
- DSP Healthcare Fund1.0% of NAV
- Bandhan BSE Healthcare Index Fund0.1% of NAV
- Motilal Oswal BSE Healthcare ETF0.1% of NAV
- Motilal Oswal BSE 1000 Index Fund0.01% of NAV
- ADITYA BIRLA SUN LIFE BSE TOTAL MARKET INDEX FUND0.01% of NAV
- ADITYA BIRLA SUN LIFE BSE TOTAL MARKET ETF0.01% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for AARTI DRUGS are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about AARTI DRUGS
What is the AARTI DRUGS share price?
AARTI DRUGS (AARTIDRUGS) last closed at ₹499.45, down 1.25% on the day. Its 52-week range is ₹319.75 to ₹508.75.
What is the market cap of AARTI DRUGS?
AARTI DRUGS has a market capitalisation of about ₹4,618 crore. Its price-to-earnings ratio is 20.3.
How are AARTI DRUGS's latest results?
AARTI DRUGS reported revenue of ₹826 crore for Sep 2026, up 26.5% from a year earlier. Net profit was ₹83 crore (up 84.4% year on year). Return on equity was 12.6% in Mar 2026. Promoter holding was 54.07% in Sep 2026, down 1.31 points over 8 quarters.
Who owns AARTI DRUGS?
As of Sep 2026, shareholding was: Promoter 54.07%, FII 2.26%, DII 10.24%, Public 33.43%.
How many mutual funds hold AARTI DRUGS?
8 mutual fund schemes held AARTI DRUGS in October 2026. That compares with 6 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 09 Feb 2026 · Interim Dividend - Rs. 2
- 04 Feb 2025 · Interim Dividend - Rs. 1
- 06 Feb 2024 · Interim Dividend - Rs. 1
- 08 Feb 2023 · Interim Dividend - Rs. 1
- 09 Feb 2022 · Interim Dividend - Rs. 1
- 03 Nov 2020 · Interim Dividend - Rs. 2.5
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.